Latest Scheme Of Arrangement News

Monash IVF has decisively turned down a non-binding acquisition offer valuing its shares at $0.80, citing significant undervaluation and uncertain financing. The Board signals openness only to proposals that deliver compelling shareholder value.

Macquarie Asset Management has tabled a $5.20 per share cash offer to acquire Qube Holdings, valuing the logistics giant at approximately $11.6 billion. The Qube board has entered an exclusivity agreement and signals unanimous support, pending due diligence and regulatory approvals.

Infomedia Ltd shares will halt trading following the Supreme Court of NSW's approval of a takeover scheme by a TPG Capital-backed entity. This marks a pivotal moment for the software company as it transitions to private ownership.

Aurumin Limited’s shares will be suspended from trading following court approval of Brightstar Resources’ acquisition scheme, marking a pivotal step in the takeover process.

The Foreign Investment Review Board has formally objected to Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma, casting serious doubt on the deal’s future and prompting Mayne to explore alternative paths.

Infomedia Ltd’s acquisition by McQueen BidCo, backed by TPG Capital, has been legally approved, triggering trading suspension and scheduled shareholder payments.

Aurumin Limited’s acquisition by Brightstar Resources has been legally approved, triggering a share exchange and imminent delisting from the ASX.

Lynch Group shareholders have overwhelmingly approved the proposed acquisition by Darwin Aus Bidco, clearing a major hurdle ahead of final court approval and trading suspension.

The Supreme Court of New South Wales has approved the acquisition of Infomedia Ltd by a TPG-managed entity, setting a clear path for the scheme’s implementation and a special dividend payout.

Lynch Group Holdings shareholders have overwhelmingly approved a $269 million acquisition scheme by Hasfarm, offering a 23% premium on recent share prices. The deal awaits final court approval before completion in December 2025.

Lynch Group Holdings Limited shareholders convened to vote on a proposed $2.155 per share acquisition by Hasfarm Bidco, with strong board and expert backing. The scheme offers a significant premium and awaits final court approval.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.